A genome-wide association study identified that single-nucleotide polymorphisms at the ABO locus were associated with plasma levels of tumor necrosis factor-α [41], which was found to be a predictor for the development of NAFLD [42]. The gene discussed is ABO; the disease is metabolic dysfunction-associated steatotic liver disease.